Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 25, 2026.

Role of C-Reactive Protein in Diabetic Inflammation

Julijana Stanimirovic, Jelena Radovanovic, Katarina Banjac and 6 more

Mediators of Inflammation · 2022 · Review

doi:10.1155/2022/3706508

Abstract

Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Type 2 diabetes mellitus (T2DM) is becoming a prime global health problem. The prevalence of T2DM quadrupled during the past 35 years and still has a constant growth projection. Moreover, we anticipate that T2DM incidence would dramatically increase with increased adolescent obesity.

Diabetes is a long-term metabolic disease in which the impaired ability of the body produce and/or respond to the hormone insulin. T2DM is characterized by abnormally elevated blood glucose levels, which affect the kidneys, heart, and blood vessels. Most diagnosed diabetes cases are type 1 diabetes mellitus (T1DM) or T2DM. T1DM, also known as juvenile diabetes, is characterized by an absolute insulin deficiency. On the other hand, T2DM is a progressive disease sustained by insulin resistance (IR) and beta cell dysfunction. The most common way to diagnose diabetes in patients is by measuring fasting plasma glucose (FPG). FPG levels less than 100 mg/dL (5.6 mmol/L) are normal glucose levels in the blood, while levels ranging from 100 to 125 mg/dL (5.6 to 6.9 mmol/L) are considered a prediabetes indicator. Patients are only diagnosed with diabetes after at least two separate tests show FPG levels higher than 126 mg/dL (7 mmol/L). Hemoglobin A1C (HbA1C) is also an indicator of T2DM, which indicates the quality of diabetes treatment since it provides healthcare professionals with information about the average blood glucose levels in the past two or three months.

Accumulating evidence corroborates the crucial role of inflammation in T2DM pathologies. Low-grade inflammation characterized by elevated inflammatory protein levels, including C-reactive protein (CRP), is linked with T2DM pathogenesis. CRP, the typical inflammatory biomarker produced in the liver, is regulated by adipocyte-derived proinflammatory cytokines, including interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α). The level of CRP is usually low in healthy individuals but can elevate 100- to 200-fold or higher in acute systemic inflammation and is chronically elevated in patients with T2DM. In individuals with T2DM, CRP levels range between 4.49 and 16.48 mg/L and among individuals with acute systemic inflammatory response syndromes from 31.08 to 226.1 mg/L.

The production of CRP may be triggered by many metabolic and inflammatory factors associated with the development of T2DM, such as increased blood glucose, adipokines, and free fatty acid levels. In addition, an increased level of CRP represents a reliable predictor of vascular complications and progression of cardiovascular disease in diabetic patients. Furthermore, numerous human and animal studies demonstrated the associations of elevated serum CRP levels with obesity and the progression of IR leading to T2DM. These findings add to the notion that the inflammatory state demonstrated by higher CRP levels is an essential factor in the pathogenesis of T2DM. Numerous studies report a significant positive association between elevated CRP levels and the risk of T2DM development. On the other hand, some studies lack this association after adjusting for many factors contributing to T2DM, including adiposity and hyperinsulinemia. Since increased body fat and obesity are among the main factors in the development of T2DM, which are also associated with increased risk for progression of obesity-related IR and inflammation, we review the published literature to collate and provide a comprehensive summary of the relationship between T2DM and CRP.

2. CRP

CRP was first described as a serum protein capable of precipitating C-polysaccharide pneumococcal cell walls during the acute phase of infective conditions in the presence of calcium. We know CRP belongs to a conserved protein family called pentraxins and has been identified in several organisms ranging from arthropods to humans. Structurally, it is a 206 amino acid cyclic pentameric protein with five identical subunits noncovalently connected, with a molecular weight of ~23 kDa (Figure 1). Each of the five subunits is similar to a discoid orientation toward a central pore folded into two antiparallel two-layered β-sheets. Native CRP (nCRP) dissociates to monomeric/modified isoform of CRP (mCRP) across lysophosphatidylcholine in platelets, apoptotic monocytic THP-1, and Jurkat T cells. Moreover, a study by Ji et al. demonstrates that nCRP, when bound to the cell membrane, dissociates into subunits while retaining some native conformation before entirely dissociating into mCRP subunits, which detaches from the membrane. This intermediate isoform, termed mCRPm, seems to have similar biological functions as mCRP, including enhancing the classical complement pathway activation and promoting proinflammatory activity. Unlike these two isoforms, nCRP displays more anti-inflammatory activities, probably because it limits the production of the membrane attack complex (MAC) and C5a, thus inhibiting the alternative complement activation. mCRP has strong angiogenic effects, both in vitro and in vivo, and likely leads to the neovascularization of tissues in which it is deposited or synthesized. Thus, treating CRP-mediated pathological conditions could include a novel therapeutic strategy that inhibits mCRP activity or prevents the dissociation of nCRP into mCRP.

CRP can recognize and bind to endogenous damage-associated molecular patterns (DAMPs) and exogenous pathogen-associated molecular patterns (PAMPs). Thus, CRP initiates an immune response and contributes to eliminating various pathogens and damaged necrotic or apoptotic cells. After binding to a specific ligand, CRP manifests anti-inflammatory features by activating the C1q molecule in the classic complement pathway engaging C3, the main adhesion molecule of the complement system, and the terminal membrane attack complex, C5–C9. In this way, CRP leads to the opsonization of the pathogen. However, CRP also acts as a proinflammatory mediator that binds to the Fcγ receptors of IgG, leading to the release of proinflammatory cytokines.

2.1. CRP Levels and Detection

The Pentraxin 1 (PTX1) gene encodes CRP, and in humans, it is located on chromosome 1q21–q23 on the long arm and consists of a long 3′ untranslated region and 2 exons. The first exon encodes two amino acids and a signal peptide, and the second exon encodes 204 amino acids. Human CRP binds to phosphocholine (PCh) across five PCh-binding locations, and every individual subunit links two calcium ions. Bacterial, eukaryotic, fungal, and endothelial cells induce PCh, and its binding to CRP is mediated mainly through Phe66 and Glu81. The C1q molecule binds and stimulates classical complement pathways on the CRP contrary site, particularly C1, C4, and C2. Baseline CRP levels are affected substantially by polymorphisms in the noncoding regions in the promoter and the untranslated region. Polymorphisms of IL-6 and IL-1 genes, which stimulate CRP production, also affect the baseline CRP levels. Groups of CRP single-nucleotide polymorphisms (SNPs) inherited together are known as five common main haplotypes, of which two are associated with higher baseline CRP levels, and two are associated with lower baseline CRP levels. Moreover, these haplotypes influence the acute phase level of CRP and the development of several diseases.

CRP participates in acute phase response to inflammation, infection, or organ trauma in humans, increasing up to 1000-fold within 24 to 72 hours. CRP is found in several cell types, including neurons, epithelial cells, monocytes, lymphocytes, and smooth muscle cells. However, the CRP gene is primarily induced in the hepatocytes due to elevated inflammatory cytokines, dominantly IL-6. Still, these extrahepatic sites do not impact CRP levels in plasma. The CRP half-life is approximately 19 hours, and its average levels are generally presented as mg/L or mg/dL. Nonetheless, CRP levels differ among laboratories since there is no optimized standard. Levels below 0.3 mg/dL are considered physiological, while levels above 10 mg/dL indicate bacterial and virus infections and severe tissue damage.

Several methods are in use for CRP detection and measurement. Immunoturbidimetry is the most commonly used method for clinical CRP determination. Conventional enzyme-linked immunosorbent assay (ELISA) and fluorescence-linked immunosorbent assay (FLISA) have also been widely used for the quantification of CRP. The main limitations of these methods are the use of complex features and the lack of cost-effectiveness. Recently, CdSe/ZnS quantum dot-based FLISA and Histag-HRP functionalized nanoconjugate-based immunoassays were developed. The main advantages of these two assays are high sensitivity, reduced time for analysis, and expanded detection range for serum samples. In addition, the assays provide a lower detection limit (LOD) and, consequently, facilitate early detection of the CRP biomarker, which is imperative for prompt diagnosis. Novel electrochemical biosensor platforms and microfluxgate sensor systems contribute to these requirements.

Levels of CRP are directly correlated with the presence and elimination of inflammatory agents. CRP's role as a diagnostic and prognostic biomarker has been established for acute infections, as well as for various chronic conditions, such as T2DM, atherosclerosis, hepatitis C, and different types of cancer. Accumulating evidence suggests a connection between the activation of the complement system and the pathogenesis of T2DM.

3. T2DM and Inflammation

T2DM is a systemic, noncommunicable disease with multiple metabolic disorders, characterized by defects in insulin secretion and/or insulin action leading to hyperglycemia. Chronic hyperglycemia induces oxidative stress, inflammation, and local and whole-body failures. Of all the types of diabetes, two forms are most common: T1DM and T2DM. T1DM occurs due to autoimmune destruction of a critical mass of pancreatic β cells, which causes a lack of insulin synthesis and secretion. Therefore, T1DM is an autoimmune disease with the rate of β cell destruction varying from rapid to slow descent. T1DM patients are rarely obese and often develop other autoimmune disorders such as Hashimoto's thyroiditis, Graves' disease, and vitiligo. This suggests that multiple genetic and environmental factors may induce the autoimmune destruction of β cells. Contrarily, T2DM is the most prevalent form, with a frequency of 90-95% of all cases in the population. T2DM characterizes a whole spectrum of events, from insulin secretion defects to the impaired action of different enzymes regulated by insulin. There are numerous causes of T2DM, but unlike T1DM, autoimmune destruction of β cells never occurs. The disease at earlier stages frequently goes undiagnosed because classic symptoms develop gradually as hyperglycemia develops, and insulin levels in such patients are often normal or elevated. Age, obesity, and lack of physical activity are probably the most crucial factors affecting the development of T2DM. Long before the clinical manifestation of T2DM, IR occurs, characterized by hyperinsulinemia often combined with obesity, hypertension, and dyslipidemia. During IR, compensatory hyperinsulinemia helps maintain normal glucose levels, but β cells lose their ability to overcome IR through hypersecretion, which leads to hyperglycemia. Subclinical inflammation is an essential part of IR, and various inflammatory markers correlate with IR, including CRP. The long-term activation of the innate immune system results in the development and progression of T2DM instead of reestablishing the normal physiological state (Figure 2). Besides CRP, the innate immune system produces acute phase response proteins, fibrinogen, and serum amyloid A, whose levels noticeably change in response to infection, tissue injury, or inflammation. High levels of CRP, fibrinogen, sialic acid, serum amyloid A, and low albumin and transferrin levels have been linked with T2DM occurrence.

Adipose tissue, especially visceral white adipose tissue (WAT), plays a significant role in T2DM's inflammatory process and development. In addition, studies demonstrated that human adipocytes could produce CRP under the stimulation of several proinflammatory cytokines, suggesting a link between obesity and its comorbidities, including IR. CRP mRNA levels in human adipose tissue also positively correlated with IL-6 mRNA levels. CRP expression in vitro was also increased by IL-6 and lipopolysaccharide stimulation, contributing to the elevated plasma CRP levels found in obese individuals. Moreover, human CRP overexpression in transgenic mice fed a high-fat diet contributed to the development of IR, hepatosteatosis, adiponectin downregulation, and expression of proinflammatory cytokines in epididymal adipose tissue. These data indicate the role of CRP in the pathogenesis of obesity-induced metabolic disorders. A recent study reported a significant decrease in weight gain and food intake, and improved insulin sensitivity was observed in CRP knockout rats placed on a high-fat diet. These results suggest that CRP is not only a biomarker of inflammation but also has a crucial role in energy balance, body weight, insulin sensitivity, and glucose homeostasis. In addition, numerous molecules such as cytokines and other bioactive substances involved in the inflammatory pathways are produced and secreted by WAT. The abdominally distributed WAT plays an essential role in the inflammatory process.

Furthermore, macrophages and immune cells infiltrate as the adipose tissue expands, contributing to local and whole-body low-grade inflammation. Adipose tissue expansion does not follow simultaneous capillaries' development, which causes adipocytes to become too distant from the vasculature. Thus, hypoxia, adipocyte cell death, and increased secretion of chemokines and adipokines may be part of the mechanisms that initiate adipose tissue inflammation. Infiltration of adipose tissue is accompanied by a decrease in anti-inflammatory M2-type macrophages, while the number of proinflammatory M1-type macrophages increases. Although T2DM does not imply autoimmune destruction of β cells, the inflammatory process in the pancreas islets does occur. It is still unclear what induces that process, but it appears to be highly dependent on IL-1 action.

Adipocyte-derived bioactive metabolites like leptin and adiponectin are also involved in T2DM pathogenesis. The leptin levels in serum are directly proportional to the total fat mass; its production increases during inflammation. Also, leptin activates and modulates innate and adaptive immune responses and promotes proinflammatory pathways. Contrarily to leptin, adiponectin is involved in anti-inflammatory pathways. Thus, low adiponectin levels are associated with T2DM incidence, which shows an inverse relationship between plasma adiponectin levels and CRP levels. Additionally, TNF-α, IL-6, and IL-10 are essential cytokines produced by adipocytes and immune cells. TNF-α and IL-6 are known proinflammatory factors, whereas IL-10 exhibits anti-inflammatory properties, and IL-6 predominantly controls CRP production by hepatocytes. Besides IL-6 and TNF-α, the liver produces IL-1, which stimulates the synthesis of acute-phase proteins. Also, the correlation between fasting insulin and CRP levels implicates the link between IR and inflammatory processes.

Inflammation of adipose tissue and high production of TNF-α, IL-6, and IL-1β in obesity is vital for T2DM incidence and progression. Some authors indicated that TNF-α contributes to the development of IR in skeletal muscle of human individuals by suppressing Akt substrate and stimulating IL-18 expression. Furthermore, TNF-α constrains insulin-stimulated glucose uptake and endothelium vasodilation. In addition, TNF-α receptors mediate the upregulation of the NF-κB pathway and influence proteins that disturb insulin signaling and proinflammatory response. Nevertheless, IL-6 affects insulin-degrading enzyme expression and activity in the liver and skeletal muscle tissues, and modulation of this enzyme may contribute to T2DM and obesity. According to a new meta-analysis, IL-6 indeed mediates chronic inflammation in T2DM. However, IL-6 influence on the general population seems insufficient, and acting on the IL-6 pathway may not reduce the risk for T2DM occurrence. Even though IL-6 is essential for liver homeostasis, only a few cell types express IL-6 receptors, including hepatocytes, and its persistent activation is associated with liver pathologies. Studies demonstrate that IL-6-inducible protein SOSC-3 promotes IR by direct binding to insulin receptors and inhibiting its kinase activity. However, the results of one study indicate anti-inflammatory properties and the homeostatic role of IL-6 in obesity-associated inflammation and IR. Also, it was demonstrated that IL-6 increases the responsiveness of macrophages to IL-4 and thus balances its shifting toward proinflammatory M1 macrophages. In addition, the results from many studies also confirmed the pleiotropic nature of IL-6 and indicate that the effects of IL-6 on inflammation differs depending on the duration of exposure, tissue type, and factors such as concentration and source of IL-6.

Growing evidence indicates the role of gut microbiota in the immune system regulation and pathogenesis of T2DM. The product of certain bacteria triggers an inflammatory cascade, including recruitment of interleukins and CRP, which leads to impaired insulin action and T2DM development. The level of imidazole propionate (ImP), a microbial-produced histidine metabolite, is higher in subjects with T2DM. Furthermore, the proposed mechanism by which microbial-derived ImP diminished glucose metabolism includes activating the p38γ-mTOR1-S6K1 signaling cascade that caused insulin receptor substrate degradation and inflammation. In addition, increased circulating levels of LPS have been recognized as an important marker that implies a link between variations in microbiota composition and inflammation in T2DM. LPS promotes IR via stimulation of Toll-like receptors on adipocytes, upregulation of NFkB, and activation of cytokines TNF-α and IL-6. In addition, lower diversity in the gut microbiota is associated with increased white blood cell counts and high sensitivity CRP (hs-CRP) levels.

Some evidence indicates the role of CRP in diabetes-induced microvascular complications, such as neuropathy, retinopathy, and nephropathy. Elevated glucose levels could trigger microvascular alterations and increased production of inflammatory factors, including CRP, IL-6, and TNF-α. Serum hs-CRP is linked with diabetic neuropathy occurrence, one of the most prevalent diabetes complications. Nevertheless, in male and female patients, symptomatic peripheral diabetic neuropathy and inflammation are related to endothelial dysfunction and elevated CRP serum levels. It is assumed that in patients with T2DM peripheral neuropathy, increased CRP levels are positively correlated with inflammation grade. Furthermore, according to data from a large cohort study where participants were monitored for one year, hs-CRP levels above 2.5 mg/L could predict neuropathy complications in T2DM. Considering hs-CRP low-cost and accessibility features, it might be a useful predictable biomarker for neurovascular disorder in T2DM.

Diabetic retinopathy (DR) is the leading cause of visual loss worldwide. Several studies have investigated the relationship between CRP levels and DR with inconsistent results. Qiu et al. observed a positive correlation between elevated hs-CRP levels in the blood and DR onset and progression. In contrast, Song et al. reported that CRP levels could be associated only with the severity of DR. Recently, it was shown that CRP levels could be associated with the stage of DR in T2DM patients. However, previous studies demonstrated that patients with higher CRP and BMI levels were less likely to develop DR. Inconsistent results from various studies may be caused by ethnical differences in CRP and BMI levels and excluding some clinical parameters such as duration of DM and complex genetic and environmental variations.

Diabetic nephropathy (DN) is a leading cause of end-stage renal disease. Numerous studies confirmed higher CRP levels in T2DM patients with DN. A study by Tang et al. demonstrated the pathogenic role of CRP in renal inflammation and fibrosis using diabetic animal models. The meta-analysis also confirmed higher hs-CRP levels in T2DM patients with DN than in healthy subjects and T2DM patients without DN. Hayashino et al. reported that serum hs-CRP levels could be a helpful factor for predicting the risk of DN developing in T2DM patients. Additionally, it was shown that higher hs-CRP levels were associated with DN complications in T2DM patients.

Although these findings open new doors in understanding diabetes pathology, further research is needed to answer current ambiguities.

4.1. Evidence from Animal Studies

Numerous animal studies have shown the essential role of CRP in infections and inflammatory processes (Table 1). CRP is synthesized in response to monocytic mediators such as IL-1 and IL-6 in the acute phase of infections. CRP recognizes and binds to specific polysaccharides in the bacterial wall and induces further complement pathway activation, leading to the opsonization of pathogens. Moreover, there is evidence of CRP involvement in proliferation and apoptotic processes through activation of Fc receptors and the consequent production of proinflammatory mediators and proapoptotic cytokines. In addition, growing evidence show CRP is not only an inflammatory marker as its level is proven to be elevated in T2DM cases (Table 1).

Zou et al. showed elevated serum CRP levels in male streptozotocin-induced Sprague-Dawley rats compared to untreated rats. The same authors noticed degenerative changes in the heart of streptozotocin-induced rats, such as irregular cardiac muscle fibers and degenerative necrosis. Furthermore, Shirpoor et al. investigated the effect of vitamin E on oxidized low-density lipoprotein, lipid profile, CRP, and VSMC proliferation of rat aorta in streptozotocin-induced Wistar rats. They found elevated CRP levels in the diabetic rats compared to the untreated rats. Additionally, the same authors reported that the antioxidative effects of vitamin E attenuated the level of CRP and arterial complications in diabetic rats. Using the same model, Talebi-Garakani and Safarzade showed that four weeks of resistance training decreases serum inflammatory markers in diabetic rats, including CRP levels. These authors also reported increased CRP levels in the diabetic rats compared to the untreated ones.

We have previously shown that rats with high-fat diet-induced obesity and IR develop cardiac hypertrophy and elevated CRP levels in serum. We also showed that estradiol treatment leads to CRP level reduction and significantly reduces heart mass in treated rats compared to untreated obese rats. In another study, Cho and colleagues reported the differentially expressed proteins in the kidney, eye, aorta, and serum of diabetic rats compared to the controls. They reported elevated serum CRP levels in diabetic rats compared to untreated rats. Beyond the high CRP level, they studied protein alterations in the vasculature and found three potential biomarkers in aorta lysate samples that could present early signs of diabetic vascular complications development. The Asgary et al. study also indicated CRP increases in alloxan-induced diabetic rats compared to untreated. The same authors concluded that four weeks of pumpkin powder administration decreased glucose, cholesterol, triglyceride, LDL, and CRP levels in diabetic rats compared to untreated diabetic rats. Interestingly, Ige et al. reported similar CRP values, and also, histological pancreas findings were entirely physiological, with small amounts of secretions in diabetic and control group rats.

The variance in study design may explain the differences in CRP levels in diabetic animals. Although alloxan induces diabetes through a different mechanism (oxidative stress through Fenton reaction) than streptozotocin (alkylation of DNA), higher doses of alloxan applied to male and female rats induce the same effects on diabetes development and alterations of CRP levels in circulation, as streptozotocin. Some authors suggest that infections in T2DM should be treated with antibiotics and indicate that medication with fluoroquinolone antibiotics may decrease elevated CRP values in diabetic rats. Nevertheless, Almatroodi et al. showed that Thymoquinone, the key active component of the medicinal plant Nigella sativa, improved CRP, antioxidant enzymes, liver enzymes, and inflammatory markers levels in diabetic rats.

4.2. Evidence from Human Studies

Accumulating evidence from human-based studies suggests that inflammation contributes to the pathogenesis of T2DM (Table 2). Several human studies show elevated CRP levels correlate with the development of T2DM, even without adjustment of other parameters, such as adiposity, hyperinsulinemia, hypertriglyceridemia, and low HDL cholesterol.

The West of Scotland Coronary Prevention Study showed that elevated CRP indicates T2DM development in men (middle-aged), independent of established risk factors, such as fasting plasma triglyceride, body mass index (BMI), and glucose. Pradhan et al. also observed elevated CRP levels in diabetic middle-aged women compared to the healthy control, supporting a possible role of inflammation in the pathogenesis of T2DM. Furthermore, Han et al. reported sex differences in the association of elevated CRP levels with the incidence of T2DM. This strong association in women may be explained by the hormone differences and the higher adiposity percentage. A study by Nakanishi et al. showed the influence of CRP on T2DM development in Japanese Americans and not in the original Japanese population, which probably indicates the impact of different lifestyles on T2DM manifestation. The possible explanation considering the link between CRP and T2DM development may be the role of oxidative stress in inducing hyperglycemia, which further promotes inflammatory response and elevation of CRP. Furthermore, it was found that oxidative stress might impair insulin endocytosis in endothelial cells and thus could lead to endothelial dysfunction and IR. Doi et al. reported a clear link between elevated CRP levels and obesity-induced hyperglycemia and T2DM in relatively lean Asian populations (Japanese population) in both sexes even after adjustment for comprehensive risk factors related to IR. Also, in the study by Marques-Vidal et al., higher hs-CRP levels were associated with all T2DM and IR markers, and these associations persevered after multivariate adjustment. Similarly, the study showed that participants with impaired glucose tolerance had higher hs-CRP levels than euglycemic subjects, although this difference became nonsignificant after BMI adjustment. Likewise, Akbarzadeh et al. reported a significant positive association between the hs-CRP level and IR markers (HOMA-IR and FIRI) and a negative association between hs-CRP level and insulin sensitivity markers (QUICKI, McAuley. and Bennett indexes). Some studies showed an association between elevated levels of CRP and leptin in diabetic, obese, and CVD subjects, suggesting the possible role of CRP in modulating leptin action. In addition, variations in leptin levels were independently associated with CRP, indicating that a regulatory loop interrelates CRP and leptin levels. Furthermore, exploring the mechanisms of leptin resistance adds to the notion that CRP, particularly the smaller mCRP, may change the action of leptin by binding to the extracellular domain of the leptin receptor. In this way, CRP contributes to the pathogenesis of obesity-related diseases, including T2DM and CVD. A study by Kanmani et al. showed a positive association between CRP levels and the incidence of T2DM in a large Korean population. In addition, the association was more noticeable among the older group (≥50 years), and the combination of CRP levels with obesity and hypertension led to increased incidence of T2DM. Lainampetch et al. reported that patients with increased baseline levels of CRP were at increased risk of developing T2DM. These findings support the premise that CRP may indirectly impair insulin sensitivity and production due to increased systemic inflammation through innate immune response alteration. Also, elevated CRP levels influence the production of adhesion molecules, including E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) that are directly involved in the regulation of insulin action and local IR. A recent retrospective case-control study imparted that elevated hs-CRP and FPG, insulin, HbA1c, HOMA-IR, and IL-6 were found in T2DM patients. The same authors concluded that obesity-induced dyslipidemia (also demonstrated in the study) causes IR and the subsequent increase in levels of inflammatory markers. Chronic inflammation in obesity disrupts glucose homeostasis causing a persistent increase in blood glucose levels. Also, IL-6 produced by the adipose tissues may stimulate CRP secretion, which further increases IR and initiates low-grade inflammation leading to the development of T2DM. On the other hand, some studies suggest that higher CRP levels and T2DM development are attenuated or missing after adjustment to a wide range of confounding factors, including adiposity and insulin sensitivity. The degree of adiposity and baseline glycemia adjustment could explain the heterogeneity between studies and suggests that CRP might not be an independent risk factor for T2DM development.

Regarding testing CRP levels, there is a standard CRP assay measuring lower (baseline) levels of this biomarker, contributing to the diagnosis of acute inflammation. Also, a frequently used and a more sensitive hs-CRP assay reflects low-grade chronic inflammatory processes having a predictive value of future CVD risk. In addition, emerging evidence supports the use of hs-CRP levels for CVD risk assessment in IR-diabetic and nondiabetic subjects. The limitation of the abovementioned human studies, which used CRP and not hs-CRP, might be apparent. However, treatment with pioglitazone, which has insulin-sensitizing and anti-inflammatory properties (combined with antilipidemic statin therapy) decreases hs-CRP levels independently of the glucose-lowering in T2DM and nondiabetic patients with increased hs-CRP levels. This suggests that hs-CRP levels in T2DM might not necessarily establish a cause-effect pathophysiological association.

Although the clinical relationship between diabetes and increased level of CRP is well established, the molecular mechanisms by which CRP potentially induces diabetes are yet to be clarified. Particular progress has been made in investigating multiple therapeutic approaches targeting different inflammatory factors. Treatment of T2DM patients with IL-1 receptor blocker or IL-1β antibodies reduced levels of IL-6 and CRP as markers of systemic inflammation, with simultaneous improvement of glycemia and insulin secretion. Treatment of obese and diabetic subjects with IκB kinase complex β (IKKβ)/nuclear factor κB (NF-κB) inhibitor, as a central proinflammatory player, decreased the level of CRP and improved insulin sensitivity and glycemia. Also, some studies showed beneficial effects of TNF antagonism therapy on CRP level reduction, with a tendency to improve β cell function, but without impact on insulin sensitivity.

5. Conclusions

Numerous prospective studies reported the association between serum CRP level and risk of incident T2DM. However, there is heterogeneity between studies, with some showing an independent positive association of CRP with T2DM incidence, while others demonstrate no association after adjustment for adiposity and IR. Since it is unequivocally associated with the development of prediabetes and diabetes-induced vascular complications, the elevated CRP might be an indirect risk factor for T2DM progression. Additionally, elevated CRP levels should be considered one more parameter in the overall assessment of T2DM risk, besides elevated FPG and HbA1C levels, abnormal OGTT, hyperinsulinemia, etc. Thus, elevated CRP levels in patients with higher T2DM risk must warn the clinician to perform available diagnostic procedures to confirm diabetes. Since the incidence of T2DM is expected to increase in the following years dramatically, further analysis of the CRP and diabetes association is needed to provide an adjunctive method for early detection of risk for this disease.

References 199

  1. 1.

    Kanmani S., Kwon M., Shin M. K., Kim M. K. Association of C-reactive protein with risk of developing type 2 Diabetes mellitus, and role of obesity and hypertension: a large population-based Korean cohort study. Scientific Reports. 2019;9(1):p. 4573.

    Not in our library10.1038/s41598-019-40987-8

  2. 2.

    Global Report on Diabetes. 2016.

    Not in our library

  3. 3.

    Chen L., Magliano D. J., Zimmet P. Z. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nature Reviews Endocrinology. 2011;8(4):228-236.

    Not in our library10.1038/nrendo.2011.183

  4. 4.

    Pulgaron E. R., Delamater A. M. Obesity and type 2 diabetes in children: epidemiology and treatment. Current Diabetes Reports. 2014;14(8):508-508.

    Not in our library10.1007/s11892-014-0508-y

  5. 5.

    Russo G. T., Giorda C. B., Cercone S., Nicolucci A., Cucinotta D., on behalf of BetaDecline Study Group. Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study. PLoS One. 2014;9(10, article e109702).

    Not in our library10.1371/journal.pone.0109702

  6. 6.

    Lee C. C., Adler A. I., Sandhu M. S., et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52(6):1040-1047.

    Not in our library10.1007/s00125-009-1338-3

  7. 7.

    Wang X., Bao W., Liu J., et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166-175.

    Not in our library10.2337/dc12-0702

  8. 8.

    Bertoni A. G., Burke G. L., Owusu J. A., et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2010;33(4):804-810.

    Not in our library10.2337/dc09-1679

  9. 9.

    Han T. S., Sattar N., Williams K., Gonzalez-Villalpando C., Lean M. E. J., Haffner S. M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25(11):2016-2021.

    Not in our library10.2337/diacare.25.11.2016

  10. 10.

    Freeman D. J., Norrie J., Caslake M. J., et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51(5):1596-1600.

    Not in our library10.2337/diabetes.51.5.1596

  11. 11.
    Role of C-Reactive Protein at Sites of Inflammation and Infection · 2018
    No notice
  12. 12.

    Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine. 1999;340(6):448-454.

    Not in our library10.1056/nejm199902113400607

  13. 13.

    Vinagre I., Sánchez-Quesada J., Sánchez-Hernández J., et al. Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovascular Diabetology. 2014;13(1):p. 34.

    Not in our library10.1186/1475-2840-13-34

  14. 14.

    Tabassum R., Mia A. R., Reza-Ul-Haq K. M., Yesmin M., Faruqui J. M. C-reactive protein level in type-2 diabetic patients attending Mymensingh Medical College Hospital, Mymensingh. Mymensingh Medical Journal. 2017;26(1):56-60.

    Not in our library

  15. 15.

    Yachnyk I. M. C-reactive protein for differential diagnosis of sepsis and systemic inflammatory response syndrome. Galician Medical Journal. 2015;22(4):53-56.

    Not in our library

  16. 16.

    Goldberg I., Shalmon D., Shteinvil R., et al. A second C-reactive protein (CRP) test to detect inflammatory burst in patients with acute bacterial infections presenting with a first relatively low CRP. Medicine. 2020;99(42, article e22551).

    Not in our library10.1097/md.0000000000022551

  17. 17.

    Mugabo Y., Li L., Renier G. The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Current Diabetes Reviews. 2010;6(1):27-34.

    Not in our library10.2174/157339910790442628

  18. 18.

    Esser N., Paquot N., Scheen A. J. Inflammatory markers and cardiometabolic diseases. Acta Clinica Belgica. 2015;70(3):193-199.

    Not in our library10.1179/2295333715y.0000000004

  19. 19.

    Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-334.

    Not in our library10.1001/jama.286.3.327

  20. 20.

    Festa A., D'Agostino R Jr, Tracy R. P., Haffner S. M., Insulin Resistance Atherosclerosis Study. Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51(4):1131-1137.

    Not in our library10.2337/diabetes.51.4.1131

  21. 21.

    Shirpoor A., Norouzi L., Nemati S., Khadem Ansari M. H. Protective effect of vitamin E against diabetes-induced oxidized LDL and aorta cell wall proliferation in rat. Iranian Biomedical Journal. 2015;19(2):117-123.

    Not in our library10.6091/ibj.1449.2015

  22. 22.

    Talebi-Garakani E., Safarzade A. Resistance training decreases serum inflammatory markers in diabetic rats. Endocrine. 2013;43(3):564-570.

    Not in our library10.1007/s12020-012-9786-9

  23. 23.

    Obradovic M., Sudar E., Zafirovic S., Stanimirovic J., Labudovic-Borovic M., Isenovic E. R. Estradiol in vivo induces changes in cardiomyocytes size in obese rats. Angiology. 2015;66(1):25-35.

    Not in our library10.1177/0003319713514477

  24. 24.

    van Woudenbergh G. J., Kuijsten A., Sijbrands E. J. G., Hofman A., Witteman J. C. M., Feskens E. J. M. Glycemic index and glycemic load and their association with C-reactive protein and incident type 2 diabetes. Journal of Nutrition and Metabolism. 2011;2011:623077.

    Not in our library10.1155/2011/623076

  25. 25.

    Thorand B., Löwel H., Schneider A., et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Archives of Internal Medicine. 2003;163(1):93-99.

    Not in our library10.1001/archinte.163.1.93

  26. 26.

    Tillett W. S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. The Journal of Experimental Medicine. 1930;52(4):561-571.

    Not in our library10.1084/jem.52.4.561

  27. 27.

    Abernethy T. J., Avery O. T. The occurrence during acute infections of a protein not normally present in the blood: i. distribution of the reactive protein in patients' sera and the effect of calcium on the flocculation reaction with c polysaccharide of pneumococcus. The Journal of Experimental Medicine. 1941;73(2):173-182.

    Not in our library10.1084/jem.73.2.173

  28. 28.

    Abernethy T. J., Francis T. Studies on the somatic c polysaccharide of pneumococcus: i. cutaneous and serological reactions in pneumonia. The Journal of Experimental Medicine. 1937;65(1):59-73.

    Not in our library10.1084/jem.65.1.59

  29. 29.
    Evolution of C-Reactive Protein · 2019
    No notice
  30. 30.

    Trpkovic A., Obradovic M., Petrovic N., Davidovic R., Sudar-Milovanovic E., Isenovic E. R., Choi S. C-reactive protein. Encyclopedia of Signaling Molecules, 2nd Edition, (edited by Sangdun Choi). 2016;1-5.

    Not in our library

  31. 31.

    Shrive A. K., Gheetham G. M. T., Holden D., et al. Three dimensional structure of human C-reactive protein. Nature Structural Biology. 1996;3(4):346-354.

    Not in our library10.1038/nsb0496-346

  32. 32.

    Eisenhardt S. U., Thiele J. R., Bannasch H., Stark G. B., Peter K. C-reactive protein: how conformational changes influence inflammatory properties. Cell Cycle. 2009;8(23):3885-3892.

    Not in our library10.4161/cc.8.23.10068

  33. 33.

    Morioka K., Sato H., Kuboyama M., Yanagida A., Shoji A. Quantification of CRP in human serum using a handheld fluorescence detection system for capillary-based ELISA. Talanta. 2021;224, article 121725.

    Not in our library10.1016/j.talanta.2020.121725

  34. 34.

    Wu Y., Potempa L. A., el Kebir D., Filep J. G. C-reactive protein and inflammation: conformational changes affect function. Biological Chemistry. 2015;396(11):1181-1197.

    Not in our library10.1515/hsz-2015-0149

  35. 35.

    Ji S. R., Wu Y., Zhu L., et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). The FASEB Journal. 2007;21(1):284-294.

    Not in our library10.1096/fj.06-6722com

  36. 36.

    Khreiss T., József L., Potempa L. A., Filep J.´. G. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation. 2004;110(17):2713-2720.

    Not in our library10.1161/01.cir.0000146846.00816.dd

  37. 37.

    Thiele J. R., Habersberger J., Braig D., et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation. 2014;130(1):35-50.

    Not in our library10.1161/circulationaha.113.007124

  38. 38.

    Turu M. M., Slevin M., Matou S., et al. C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biology. 2008;9(1):p. 47.

    Not in our library10.1186/1471-2121-9-47

  39. 39.

    Slevin M., Matou S., Zeinolabediny Y., et al. Monomeric C-reactive protein-a key molecule driving development of Alzheimer's disease associated with brain ischaemia? Scientific Reports. 2015;5(1):p. 13281.

    Not in our library10.1038/srep13281

  40. 40.

    Shrivastava A. K., Singh H. V., Raizada A., Singh S. K. C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal. 2015;67(2):89-97.

    Not in our library10.1016/j.ehj.2014.11.005

  41. 41.

    Shim K., Begum R., Yang C., Wang H. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World Journal of Diabetes. 2020;11(1):1-12.

    Not in our library10.4239/wjd.v11.i1.1

  42. 42.

    Volanakis J. E. Complement activation by C-reactive protein complexes. Annals of the New York Academy of Sciences. 1982;389(1 C-Reactive Pr):235-250.

    Not in our library10.1111/j.1749-6632.1982.tb22140.x

  43. 43.

    Mold C., Gewurz H., Du Clos T. W. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42(1-3):23-30.

    Not in our library10.1016/s0162-3109(99)00007-7

  44. 44.

    Du Clos T. W. Function of C-reactive protein. Annals of Medicine. 2000;32(4):274-278.

    Not in our library10.3109/07853890009011772

  45. 45.

    Nehring S. M., Goyal A., Patel B. C. C Reactive Protein. 2020.

    Not in our library

  46. 46.

    Boras E., Slevin M., Alexander M. Y., et al. Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signalling pathway. Cytokine. 2014;69(2):165-179.

    Not in our library10.1016/j.cyto.2014.05.027

  47. 47.

    Srikantiah C. C - reactive protein: an inflammatory marker with specific role in physiology, pathology, and diagnosis. Internet Journal of Rheumatology and Clinical Immunology. 2014;2(S1).

    Not in our library10.15305/ijrci/v2is1/117

  48. 48.

    Thompson D., Pepys M. B., Wood S. P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7(2):169-177.

    Not in our library10.1016/s0969-2126(99)80023-9

  49. 49.

    Kaplan M. H., Volanakis J. E. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. Journal of Immunology. 1974;112(6):2135-2147.

    Not in our library

  50. 50.
    Pentraxins: Structure, Function, and Role in Inflammation · 2013
    No notice
  51. 51.

    Dehghan A., Dupuis J., Barbalic M., et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011;123(7):731-738.

    Not in our library10.1161/circulationaha.110.948570

  52. 52.

    Rhodes B., Fürnrohr B. G., Vyse T. J. C-reactive protein in rheumatology: biology and genetics. Nature Reviews Rheumatology. 2011;7(5):282-289.

    Not in our library10.1038/nrrheum.2011.37

  53. 53.

    Goldberger G., Bing D. H., Sipe J. D., Rits M., Colten H. R. Transcriptional regulation of genes encoding the acute-phase proteins CRP, SAA, and C3. Journal of Immunology. 1987;138(11):3967-3971.

    Not in our library

  54. 54.

    Pepys M. B., Baltz M. L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Advances in Immunology. 1983;34:141-212.

    Not in our library10.1016/s0065-2776(08)60379-x

  55. 55.

    Kilpatrick J. M., Volanakis J. E. Molecular genetics, structure, and function of C-reactive protein. Immunologic Research. 1991;10(1):43-53.

    Not in our library10.1007/bf02918166

  56. 56.

    Shine B., de Beer F. C., Pepys M. B. Solid phase radioimmunoassays for human C-reactive protein. Clinica Chimica Acta. 1981;117(1):13-23.

    Not in our library10.1016/0009-8981(81)90005-x

  57. 57.

    Nehring S. M., Goyal A., Patel B. C. C Reactive Protein. StatPearls. 2021.

    Not in our library

  58. 58.

    Dupuy A. M., Badiou S., Descomps B., Cristol J. P. Immunoturbidimetric determination of C-reactive protein (CRP) and high-sensitivity CRP on heparin plasma. Comparison with serum determination. Clinical Chemistry and Laboratory Medicine. 2003;41(7):948-949.

    Not in our library10.1515/cclm.2003.144

  59. 59.

    Şişman A. R., Küme T., Taş G., Akan P. N., Tuncel P. N. Comparison and evaluation of two C-reactive protein assays based on particle-enhanced immunoturbidimetry. Journal of Clinical Laboratory Analysis. 2007;21(2):71-76.

    Not in our library10.1002/jcla.20141

  60. 60.

    Wu T. L., Tsao K. C., Chang C. P. Y., Li C. N., Sun C. F., Wu J. T. Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. Clinica Chimica Acta. 2002;322(1-2):163-168.

    Not in our library10.1016/s0009-8981(02)00172-9

  61. 61.

    Lv Y., Wu R., Feng K., et al. Highly sensitive and accurate detection of C-reactive protein by CdSe/ZnS quantum dot-based fluorescence-linked immunosorbent assay. Journal of Nanobiotechnology. 2017;15(1):p. 35.

    Not in our library10.1186/s12951-017-0267-4

  62. 62.

    Siddiqui M. F., Khan Z. A., Park S. Detection of C-reactive protein using Histag-HRP functionalized nanoconjugate with signal amplified immunoassay. Nanomaterials. 2020;10(6):p. 1240.

    Not in our library10.3390/nano10061240

  63. 63.

    Sardesai A. U., Dhamu V. N., Paul A., Muthukumar S., Prasad S. Design and electrochemical characterization of spiral electrochemical notification coupled electrode (SENCE) Platform for Biosensing Application. Platform for Biosensing Application. 2020;11(3):p. 333.

    Not in our library10.3390/mi11030333

  64. 64.

    Ma Y., Yang J., Yang T., et al. Electrochemical detection of C-reactive protein using functionalized iridium nanoparticles/graphene oxide as a tag. RSC Advances. 2020;10(16):9723-9729.

    Not in our library10.1039/c9ra10386d

  65. 65.

    Guo L., Yang Z., Zhi S., Feng Z., Lei C., Zhou Y. A sensitive and innovative detection method for rapid C-reactive proteins analysis based on a micro-fluxgate sensor system. PLoS One. 2018;13(3, article e0194631).

    Not in our library10.1371/journal.pone.0194631

  66. 66.

    Vanderschueren S., Deeren D., Knockaert D. C., Bobbaers H., Bossuyt X., Peetermans W. Extremely elevated C-reactive protein. European Journal of Internal Medicine. 2006;17(6):430-433.

    Not in our library10.1016/j.ejim.2006.02.025

  67. 67.

    Tian T., Wei B., Wang J. Study of C-reactive protein, procalcitonin, and immunocyte ratios in 194 patients with sepsis. BMC Emergency Medicine. 2021;21(1):p. 81.

    Not in our library10.1186/s12873-021-00477-5

  68. 68.

    Sayit A. T., Elmali M., Deveci A., Gedikli O. Relationship between acute phase reactants and prognosis in patients with or without COVID-19 pneumonia. Revista do Instituto de Medicina Tropical de São Paulo. 2021;63, article e51.

    Not in our library10.1590/s1678-9946202163051

  69. 69.

    Ali A., Noman M., Guo Y., et al. Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. Scientific Reports. 2021;11(1):p. 5975.

    Not in our library10.1038/s41598-021-85426-9

  70. 70.

    Zhou H.-T., Zhao D. L., Wang G. K., Wang T. Z., Liang H. W., Zhang J. L. Assessment of high sensitivity C-reactive protein and coronary plaque characteristics by computed tomography in patients with and without diabetes mellitus. BMC Cardiovascular Disorders. 2020;20(1):p. 435.

    Not in our library10.1186/s12872-020-01704-w

  71. 71.
    C-Reactive Protein in Atherothrombosis and Angiogenesis · 2018
    No notice
  72. 72.

    de Souza Pires-Neto O., da Silva Graça Amoras E., Queiroz M. A. F., et al. Hepatic TLR4, MBL and CRP gene expression levels are associated with chronic hepatitis C. Infection, Genetics and Evolution. 2020;80, article 104200.

    Not in our library10.1016/j.meegid.2020.104200

  73. 73.

    Socha M. W., Malinowski B., Puk O., et al. C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. Critical Reviews in Oncology/Hematology. 2021;164, article 103419.

    Not in our library10.1016/j.critrevonc.2021.103419

  74. 74.

    Deng Y., Zhao Y., Qin J., et al. Prognostic value of the C-reactive protein/albumin ratio and systemic immune-inflammation index for patients with colorectal liver metastasis undergoing curative resection. Pathology Oncology Research. 2021;27, article 633480.

    Not in our library10.3389/pore.2021.633480

  75. 75.

    Engstrom G., Hedblad B., Eriksson K. F., Janzon L., Lindgarde F. ComplementC3 is a risk factor for the development of Diabetes. Diabetes. 2005;54(2):570-575.

    Not in our library10.2337/diabetes.54.2.570

  76. 76.

    Engström G., Hedblad B., Janzon L., Lindgärde F. Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study. Diabetologia. 2005;48(12):2525-2531.

    Not in our library10.1007/s00125-005-0021-6

  77. 77.

    Wlazlo N., van Greevenbroek M. M. J., Ferreira I., et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM study. Diabetes Care. 2014;37(7):1900-1909.

    Not in our library10.2337/dc13-2804

  78. 78.

    Oguntibeju O. O. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. International Journal of Physiology, Pathophysiology and Pharmacology. 2019;11(3):45-63.

    Not in our library

  79. 79.

    Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1(Suppl 1):S62-S69.

    Not in our library10.2337/dc10-s062

  80. 80.

    Ramalingam L., Menikdiwela K., LeMieux M., et al. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2017;1863(5):1106-1114.

    Not in our library10.1016/j.bbadis.2016.07.019

  81. 81.

    Atkinson M. A., Eisenbarth G. S., Michels A. W. Type 1 diabetes. The Lancet. 2014;383(9911):69-82.

    Not in our library10.1016/s0140-6736(13)60591-7

  82. 82.

    Festa A., D’Agostino R., Howard G., Mykkänen L., Tracy R. P., Haffner S. M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-47.

    Not in our library10.1161/01.cir.102.1.42

  83. 83.

    Fujimoto W. Y. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. The American Journal of Medicine. 2000;108(6):9-14.

    Not in our library10.1016/s0002-9343(00)00337-5

  84. 84.

    Obradovic M., Sudar-Milovanovic E., Gluvic Z., Gojobori T., Essack M., Isenovic E. R., Faintuch J., Faintuch S. Diabetes and treatments. Obesity and Diabetes: Scientific Advances and Best Practice. 2020;705-717.

    Not in our library

  85. 85.

    Rao G. Insulin resistance syndrome. American Family Physician. 2001;63(6):1159-1163.

    Not in our library

  86. 86.

    Trpkovic A., Stanimirovic J., Resanovic I., et al. High sensitivity C-reactive protein and cardiovascular risk prediction. Current Pharmaceutical Analysis. 2014;11(1):60-65.

    Not in our library10.2174/1573412910666140822003911

  87. 87.

    Obradovic M. M., Trpkovic A., Bajic V., et al. Interrelatedness between C-reactive protein and oxidized low-density lipoprotein. Clinical Chemistry and Laboratory Medicine. 2015;53(1):29-34.

    Not in our library10.1515/cclm-2014-0590

  88. 88.
    Acute-phase proteins: As diagnostic tool · 2011
    No notice
  89. 89.

    Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabetic Medicine. 2004;21(3):203-207.

    Not in our library10.1046/j.1464-5491.2003.01030.x

  90. 90.

    Calabro P., Chang D. W., Willerson J. T., Yeh E. T. H. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. Journal of the American College of Cardiology. 2005;46(6):1112-1113.

    Not in our library10.1016/j.jacc.2005.06.017

  91. 91.

    Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671-674.

    Not in our library10.1161/01.cir.0000055188.83694.b3

  92. 92.

    Uemura H., Katsuura-Kamano S., Yamaguchi M., et al. Relationships of serum high-sensitivity C-reactive protein and body size with insulin resistance in a Japanese cohort. PLoS One. 2017;12(6, article e0178672).

    Not in our library10.1371/journal.pone.0178672

  93. 93.

    Anty R., Bekri S., Luciani N., et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. The American Journal of Gastroenterology. 2006;101(8):1824-1833.

    Not in our library10.1111/j.1572-0241.2006.00724.x

  94. 94.

    Kaneko H., Anzai T., Nagai T., et al. Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling. Cardiovascular Research. 2011;91(3):546-555.

    Not in our library10.1093/cvr/cvr088

  95. 95.

    Yang M., Qiu S., He Y., et al. Genetic ablation of C-reactive protein gene confers resistance to obesity and insulin resistance in rats. Diabetologia. 2021;64(5):1169-1183.

    Not in our library10.1007/s00125-021-05384-9

  96. 96.

    Lontchi-Yimagou E., Sobngwi E., Matsha T. E., Kengne A. P. Diabetes mellitus and inflammation. Current Diabetes Reports. 2013;13(3):435-444.

    Not in our library10.1007/s11892-013-0375-y

  97. 97.

    Trayhurn P. Adipose tissue in obesity—an inflammatory issue. Endocrinology. 2005;146(3):1003-1005.

    Not in our library10.1210/en.2004-1597

  98. 98.

    Wellen K. E., Hotamisligil G. S. Obesity-induced inflammatory changes in adipose tissue. The Journal of Clinical Investigation. 2003;112(12):1785-1788.

    Not in our library10.1172/jci20514

  99. 99.

    Iikuni N., Kwan Lam Q., Lu L., Matarese G., Cava A. Leptin and inflammation. Current Immunology Reviews. 2008;4(2):70-79.

    Not in our library10.2174/157339508784325046

  100. 100.

    Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clinica Chimica Acta. 2007;380(1-2):24-30.

    Not in our library10.1016/j.cca.2007.01.026

  101. 101.

    Wellen K. E., Hotamisligil G. S. Inflammation, stress, and diabetes. The Journal of Clinical Investigation. 2005;115(5):1111-1119.

    Not in our library10.1172/jci25102

  102. 102.

    Borst S. E. The role of TNF-α in insulin resistance. Endocrine. 2004;23(2-3):177-182.

    Not in our library10.1385/endo:23:2-3:177

  103. 103.

    Burhans M. S., Hagman D. K., Kuzma J. N., Schmidt K. A., Kratz M. Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Comprehensive Physiology. 2018;9(1):1-58.

    Not in our library10.1002/cphy.c170040

  104. 104.

    Plomgaard P., Bouzakri K., Krogh-Madsen R., Mittendorfer B., Zierath J. R., Pedersen B. K. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54(10):2939-2945.

    Not in our library10.2337/diabetes.54.10.2939

  105. 105.

    Krogh-Madsen R., Plomgaard P., Møller K., Mittendorfer B., Pedersen B. K. Influence of TNF-α and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. American Journal of Physiology. Endocrinology and Metabolism. 2006;291(1):E108-E114.

    Not in our library10.1152/ajpendo.00471.2005

  106. 106.

    Rask-Madsen C., Domínguez H., Ihlemann N., Hermann T., Køber L., Torp-Pedersen C. Tumor Necrosis Factor-α Inhibits Insulin’s Stimulating Effect on Glucose Uptake and Endothelium-Dependent Vasodilation in Humans. Circulation. 2003;108(15):1815-1821.

    Not in our library10.1161/01.cir.0000091406.72832.11

  107. 107.

    Mohallem R., Aryal U. K. Regulators of TNFα mediated insulin resistance elucidated by quantitative proteomics. Scientific Reports. 2020;10(1):p. 20878.

    Not in our library10.1038/s41598-020-77914-1

  108. 108.

    Kurauti M. A., Costa-Júnior J. M., Ferreira S. M., et al. Interleukin-6 increases the expression and activity of insulin-degrading enzyme. Scientific Reports. 2017;7(1):p. 46750.

    Not in our library10.1038/srep46750

  109. 109.
    Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes · 2020
    Not checked
  110. 110.

    Schmidt-Arras D., Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. Journal of Hepatology. 2016;64(6):1403-1415.

    Not in our library10.1016/j.jhep.2016.02.004

  111. 111.

    Klover P. J., Mooney R. A. Hepatocytes: critical for glucose homeostasis. The International Journal of Biochemistry & Cell Biology. 2004;36(5):753-758.

    Not in our library10.1016/j.biocel.2003.10.002

  112. 112.

    Mauer J., Chaurasia B., Goldau J., et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nature Immunology. 2014;15(5):423-430.

    Not in our library10.1038/ni.2865

  113. 113.

    Akbari M., Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018;26(3):685-698.

    Not in our library10.1007/s10787-018-0458-0

  114. 114.

    Goldman J. L., Sammani S., Kempf C., et al. Pleiotropic effects of interleukin-6 in a “two-hit” murine model of acute respiratory distress syndrome. Pulmonary Circulation. 2014;4(2):280-288.

    Not in our library10.1086/675991

  115. 115.

    Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Research & Therapy. 2006;8(2):p. S2.

    Not in our library10.1186/ar1916

  116. 116.

    Knüpfer H., Preiß R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Research and Treatment. 2007;102(2):129-135.

    Not in our library10.1007/s10549-006-9328-3

  117. 117.

    Rohleder N., Aringer M., Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. Annals of the New York Academy of Sciences. 2012;1261(1):88-96.

    Not in our library10.1111/j.1749-6632.2012.06634.x

  118. 118.
    The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation · 2020
    No notice
  119. 119.
    Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes · 2020
    No notice
  120. 120.
    Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology · 2020
    Corrected
  121. 121.

    van den Munckhof I. C. L., Kurilshikov A., ter Horst R., et al. Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obesity Reviews. 2018;19(12):1719-1734.

    Not in our library10.1111/obr.12750

  122. 122.
    The Gut Microbiota and Inflammation: An Overview · 2020
    No notice
  123. 123.
    Aberrant intestinal microbiota in individuals with prediabetes · 2018
    No notice
  124. 124.

    Wu H., Tremaroli V., Schmidt C., et al. The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study. Cell Metabolism. 2020;32(3):379-390.e3.

    Not in our library10.1016/j.cmet.2020.06.011

  125. 125.

    Koh A., Molinaro A., Ståhlman M., et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018;175(4):947-961.e17.

    Not in our library10.1016/j.cell.2018.09.055

  126. 126.

    Koh A., Mannerås-Holm L., Yunn N. O., et al. Microbial imidazole propionate affects responses to metformin through p38γ-dependent inhibitory AMPK phosphorylation. Cell Metabolism. 2020;32(4):643-653.e4.

    Not in our library10.1016/j.cmet.2020.07.012

  127. 127.

    Creely S. J., McTernan P. G., Kusminski C. M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. American Journal of Physiology. Endocrinology and Metabolism. 2007;292(3):E740-E747.

    Not in our library10.1152/ajpendo.00302.2006

  128. 128.

    Ghanim H., Abuaysheh S., Sia C. L., et al. Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care. 2009;32(12):2281-2287.

    Not in our library10.2337/dc09-0979

  129. 129.

    Chung S., LaPoint K., Martinez K., Kennedy A., Boysen Sandberg M., McIntosh M. K. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology. 2006;147(11):5340-5351.

    Not in our library10.1210/en.2006-0536

  130. 130.

    Claesson M. J., Jeffery I. B., Conde S., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488(7410):178-184.

    Not in our library10.1038/nature11319

  131. 131.

    Gasecka A., Siwik D., Gajewska M., et al. Early biomarkers of neurodegenerative and neurovascular disorders in diabetes. Journal of Clinical Medicine. 2020;9(9):p. 9.

    Not in our library10.3390/jcm9092807

  132. 132.

    Papanas N., Katsiki N., Papatheodorou K., et al. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology. 2011;62(4):291-295.

    Not in our library10.1177/0003319710394164

  133. 133.

    Zhang H. H., Han X., Wang M., et al. The association between genomic DNA methylation and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Journal of Diabetes Research. 2019;2019.

    Not in our library10.1155/2019/2494057

  134. 134.

    Zhang G., Wei W., Tan B., Liu J. Correlations between hormone levels and cardiovascular autonomic neuropathy in menopausal patients with diabetes mellitus. Pakistan Journal of Medical Sciences. 2020;36(6):1382-1386.

    Not in our library10.12669/pjms.36.6.2088

  135. 135.

    Doupis J., Lyons T. E., Wu S., Gnardellis C., Dinh T., Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. The Journal of Clinical Endocrinology and Metabolism. 2009;94(6):2157-2163.

    Not in our library10.1210/jc.2008-2385

  136. 136.

    Aryan Z., Ghajar A., Faghihi-Kashani S., Afarideh M., Nakhjavani M., Esteghamati A. Baseline high-sensitivity C-reactive protein predicts macrovascular and microvascular complications of type 2 diabetes: a population-based study. Annals of Nutrition & Metabolism. 2018;72(4):287-295.

    Not in our library10.1159/000488537

  137. 137.

    Qiu F., Ma X., Shin Y. H., et al. Pathogenic role of human C-reactive protein in diabetic retinopathy. Clinical Science. 2020;134(13):1613-1629.

    Not in our library10.1042/cs20200085

  138. 138.

    Song J., Chen S., Liu X., Duan H., Kong J., Li Z. Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis. PLoS One. 2015;10(12, article e0144406).

    Not in our library10.1371/journal.pone.0144406

  139. 139.
    Correlation of C-reactive protein and BMI with severity of diabetic retinopathy · 2022
    Not checked
  140. 140.

    Lim L. S., Tai E. S., Mitchell P., et al. C-reactive protein, body mass index, and diabetic retinopathy. Investigative Ophthalmology & Visual Science. 2010;51(9):4458-4463.

    Not in our library10.1167/iovs.09-4939

  141. 141.

    Tang P. M.-K., Zhang Y. Y., Hung J. S. C., et al. DPP4/CD32b/NF-κB circuit: a novel druggable target for inhibiting CRP-driven diabetic nephropathy. Molecular Therapy. 2021;29(1):365-375.

    Not in our library10.1016/j.ymthe.2020.08.017

  142. 142.

    Liu Q., Jiang C. Y., Chen B. X., Zhao W., Meng D. The association between high-sensitivity C-reactive protein concentration and diabetic nephropathy: a meta-analysis. European Review for Medical and Pharmacological Sciences. 2015;19(23):4558-4568.

    Not in our library

  143. 143.

    Hayashino Y., Mashitani T., Tsujii S., Ishii H., Diabetes Distress and Care Registry at Tenri Study Group. Serum high-sensitivity C-reactive protein levels are associated with high risk of development, not progression, of diabetic nephropathy among Japanese type 2 diabetic patients: a prospective cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT7]). Diabetes Care. 2014;37(11):2947-2952.

    Not in our library10.2337/dc14-1357

  144. 144.

    Fu C. C., Wu D. A., Wang J. H., Yang W. C., Tseng C. H. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetologica. 2009;46(2):127-134.

    Not in our library10.1007/s00592-008-0069-0

  145. 145.

    Varma V., Varma M., Varma A., Kumar R., Bharosay A., Vyas S. Serum Total sialic acid and highly sensitive C-reactive protein: prognostic markers for the diabetic nephropathy. Journal of Laboratory Physicians. 2016;8(1):025-029.

    Not in our library10.4103/0974-2727.176230

  146. 146.

    Marnell L., Mold C., Du Clos T. W. C-reactive protein: ligands, receptors and role in inflammation. Clinical Immunology. 2005;117(2):104-111.

    Not in our library10.1016/j.clim.2005.08.004

  147. 147.

    Ryu J., Lee C., Shin J., et al. FcγRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovascular Research. 2007;75(3):555-565.

    Not in our library10.1016/j.cardiores.2007.04.027

  148. 148.

    Zou X. L., Yang J., Yang J. M., et al. Brief communication (original). Immune injury in rat models of type 2 diabetes mellitus. Asian Biomedicine. 2017;6(6):903-908.

    Not in our library

  149. 149.

    Cho W. C., Yip T. T., Chung W. S., Leung A. W., Cheng C. H., Yue K. K. Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. Journal of Cellular Biochemistry. 2006;99(1):256-268.

    Not in our library10.1002/jcb.20923

  150. 150.

    Asgary S. Hypoglycaemic and hypolipidemic effects of pumpkin (Cucurbita pepo L.) on alloxan-induced diabetic rats. African Journal of Pharmacy and Pharmacology. 2011;5(23).

    Not in our library10.5897/ajpp11.635

  151. 151.

    Ige A. O., Ajayi O. A., Adewoye E. O. Anti-inflammatory and insulin secretory activity in experimental type-2 diabetic rats treated orally with magnesium. Journal of Basic and Clinical Physiology and Pharmacology. 2018;29(5):507-514.

    Not in our library10.1515/jbcpp-2017-0104

  152. 152.

    Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological Research. 2001;50(6):537-546.

    Not in our library

  153. 153.

    Obasi D. C., Ogugua V. N. GC-MS analysis, pH and antioxidant effect of Ruzu herbal bitters on alloxan-induced diabetic rats. Biochemistry and Biophysics Reports. 2021;27, article 101057.

    Not in our library10.1016/j.bbrep.2021.101057

  154. 154.

    Yusuf B. O., Yakubu M. T., Akanji M. A. Chromatographic fractions from _Chrysophyllum albidum_ stem bark boost antioxidant enzyme activity and ameliorate some markers of diabetes complications. Journal of Traditional and Complementary Medicine. 2021;11(4):336-342.

    Not in our library10.1016/j.jtcme.2021.01.005

  155. 155.

    Gharib H. M., Abajy M. Y., Omaren A. Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-induced blood pressure reduction deviations after aging of diabetes in STZ-induced diabetic Wistar rats. Heliyon. 2020;6(4, article e03812).

    Not in our library10.1016/j.heliyon.2020.e03812

  156. 156.

    Almatroodi S. A., Alnuqaydan A. M., Alsahli M. A., Khan A. A., Rahmani A. H. Thymoquinone, the Most prominent constituent of nigella sativa, attenuates liver damage in streptozotocin-induced diabetic rats via regulation of oxidative stress, inflammation and cyclooxygenase-2 protein expression. Applied Sciences. 2021;11(7):p. 3223.

    Not in our library10.3390/app11073223

  157. 157.

    Thorand B., Baumert J., Kolb H., et al. Sex differences in the prediction of type 2 diabetes by inflammatory Markers. Diabetes Care. 2007;30(4):854-860.

    Not in our library10.2337/dc06-1693

  158. 158.

    Nakanishi S., Yamane K., Kamei N., Okubo M., Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003;26(10):2754-2757.

    Not in our library10.2337/diacare.26.10.2754

  159. 159.

    Nishikawa T., Edelstein D., du X. L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787-790.

    Not in our library10.1038/35008121

  160. 160.

    Arnalich F., Hernanz A., López-Maderuelo D., et al. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Hormone and Metabolic Research. 2000;32(10):407-412.

    Not in our library10.1055/s-2007-978662

  161. 161.

    Bertelsen M., Anggård E. E., Carrier M. J. Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia. 2001;44(5):605-613.

    Not in our library10.1007/s001250051667

  162. 162.

    Gopaul N. K., Manraj M. D., Hébé A., et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia. 2001;44(6):706-712.

    Not in our library10.1007/s001250051679

  163. 163.

    Doi Y., Kiyohara Y., Kubo M., et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care. 2005;28(10):2497-2500.

    Not in our library10.2337/diacare.28.10.2497

  164. 164.

    Marques-Vidal P., Bastardot F., von Känel R., et al. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clinical Endocrinology. 2013;78(2):232-241.

    Not in our library10.1111/j.1365-2265.2012.04384.x

  165. 165.

    Akbarzadeh M., Eftekhari M. H., Dabbaghmanesh M. H., Hasanzadeh J., Bakhshayeshkaram M. Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes. Iranian Journal of Immunology. 2013;10(3):167-176.

    Not in our library10.22034/iji.2013.16832

  166. 166.

    Yanagawa T., Taniguchi A., Fukushima M., et al. Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. Diabetes Research and Clinical Practice. 2007;75(1):2-6.

    Not in our library10.1016/j.diabres.2006.04.019

  167. 167.

    van Dielen F. M., van't Veer C., Schols A. M., Soeters P. B., Buurman W. A., Greve J. W. M. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. International Journal of Obesity and Related Metabolic Disorders. 2001;25(12):1759-1766.

    Not in our library10.1038/sj.ijo.0801825

  168. 168.

    Gómez-Ambrosi J., Salvador J., Páramo J. A., et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clinical Biochemistry. 2002;35(4):315-320.

    Not in our library10.1016/s0009-9120(02)00320-x

  169. 169.

    Park J. S., Cho M. H., Nam J. S., et al. Visceral adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients. Acta Diabetologica. 2010;47(2):113-118.

    Not in our library10.1007/s00592-009-0125-4

  170. 170.

    Sudhakar M., Silambanan S., Chandran A. S., Prabhakaran A. A., Ramakrishnan R. C-reactive protein (CRP) and leptin receptor in obesity: binding of monomeric CRP to leptin receptor. Frontiers in Immunology. 2018;9:1167-1167.

    Not in our library10.3389/fimmu.2018.01167

  171. 171.

    Shamsuzzaman A. S., Winnicki M., Wolk R., et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation. 2004;109(18):2181-2185.

    Not in our library10.1161/01.cir.0000127960.28627.75

  172. 172.
    Leptin and Obesity: Role and Clinical Implication · 2021
    No notice
  173. 173.

    Lainampetch J., Panprathip P., Phosat C., et al. Association of tumor necrosis factor alpha, interleukin 6, and C-reactive protein with the risk of developing type 2 diabetes: a retrospective cohort study of rural Thais. Journal of Diabetes Research. 2019;2019.

    Not in our library10.1155/2019/9051929

  174. 174.

    Pickup J. C., Crook M. A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41(10):1241-1248.

    Not in our library10.1007/s001250051058

  175. 175.

    Calle M. C., Fernandez M. L. Inflammation et diabete de type 2. Diabetes & Metabolism. 2012;38(3):183-191.

    Not in our library10.1016/j.diabet.2011.11.006

  176. 176.

    Nisar M., Iqbal M. U. Influence of hs-CRP, IL-6 and TNF-α and it's role in dyslipidemia and type 2 diabetes in population of Karachi, Pakistan. Pakistan Journal of Pharmaceutical Sciences. 2021;34(3(Special)):1217-1225.

    Not in our library

  177. 177.

    Tsalamandris S., Antonopoulos A. S., Oikonomou E., et al. The role of inflammation in Diabetes: current concepts and future perspectives. European Cardiology. 2019;14(1):50-59.

    Not in our library10.15420/ecr.2018.33.1

  178. 178.

    Mtintsilana A., Micklesfield L. K., Chorell E., et al. Adiposity mediates the association between the dietary inflammatory index and markers of type 2 diabetes risk in middle-aged Black South African women. Nutrients. 2019;11(6):p. 1246.

    Not in our library10.3390/nu11061246

  179. 179.

    Camhi S. M., Stefanick M. L., Ridker P. M., Young D. R. Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome. Metabolism. 2010;59(1):54-61.

    Not in our library10.1016/j.metabol.2009.07.008

  180. 180.

    Forst T., Karagiannis E., Lübben G., et al. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis. 2008;197(1):311-317.

    Not in our library10.1016/j.atherosclerosis.2007.05.006

  181. 181.

    Hanefeld M., Marx N., Pfützner A., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. Journal of the American College of Cardiology. 2007;49(3):290-297.

    Not in our library10.1016/j.jacc.2006.08.054

  182. 182.

    Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26(9):2493-2499.

    Not in our library10.2337/diacare.26.9.2493

  183. 183.

    Pfützner A., Marx N., Lübben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. Journal of the American College of Cardiology. 2005;45(12):1925-1931.

    Not in our library10.1016/j.jacc.2005.03.041

  184. 184.

    Larsen C. M., Faulenbach M., Vaag A., et al. Interleukin-1–receptor antagonist in type 2 diabetes mellitus. New England Journal of Medicine. 2007;356(15):1517-1526.

    Not in our library10.1056/nejmoa065213

  185. 185.

    Larsen C. M., Faulenbach M., Vaag A., Ehses J. A., Donath M. Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32(9):1663-1668.

    Not in our library10.2337/dc09-0533

  186. 186.

    Sloan-Lancaster J., Abu-Raddad E., Polzer J., et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care. 2013;36(8):2239-2246.

    Not in our library10.2337/dc12-1835

  187. 187.

    Hensen J., Howard C. P., Walter V., Thuren T. Incidence de l'anticorps anti-interleukine-1β (canakinumab) sur les indicateurs de glycemie chez les patients atteints de diabete de type 2: resultats des criteres d'evaluation secondaires d'un essai a repartition aleatoire et controle par placebo. Diabetes & Metabolism. 2013;39(6):524-531.

    Not in our library10.1016/j.diabet.2013.07.003

  188. 188.

    Ridker P. M., Howard C. P., Walter V., et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739-2748.

    Not in our library10.1161/circulationaha.112.122556

  189. 189.

    Everett B. M., Donath M. Y., Pradhan A. D., et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. Journal of the American College of Cardiology. 2018;71(21):2392-2401.

    Not in our library10.1016/j.jacc.2018.03.002

  190. 190.

    Fleischman A., Shoelson S. E., Bernier R., Goldfine A. B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289-294.

    Not in our library10.2337/dc07-1338

  191. 191.

    Goldfine A. B., Silver R., Aldhahi W., et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and Translational Science. 2008;1(1):36-43.

    Not in our library10.1111/j.1752-8062.2008.00026.x

  192. 192.

    Dominguez H., Storgaard H., Rask-Madsen C., et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. Journal of Vascular Research. 2005;42(6):517-525.

    Not in our library10.1159/000088261

  193. 193.

    Bernstein L. E., Berry J., Kim S., Canavan B., Grinspoon S. K. Effects of etanercept in patients with the metabolic syndrome. Archives of Internal Medicine. 2006;166(8):902-908.

    Not in our library10.1001/archinte.166.8.902

  194. 194.

    Kato K., Otsuka T., Saiki Y., et al. Association between elevated C-reactive protein levels and prediabetes in adults, particularly impaired glucose tolerance. Canadian Journal of Diabetes. 2019;43(1):40-45.e2.

    Not in our library10.1016/j.jcjd.2018.03.007

  195. 195.

    Kato K., Otsuka T., Saiki Y., et al. Elevated C-reactive protein levels independently predict the development of prediabetes markers in subjects with normal glucose regulation. Experimental and Clinical Endocrinology & Diabetes. 2021;129(4):289-295.

    Not in our library10.1055/a-0869-7584

  196. 196.

    Zheng Z., Yin Y., Lu R. Lycopene ameliorated oxidative stress and inflammation in Type 2 diabetic rats. Journal of Food Science. 2019;84(5):1194-1200.

    Not in our library10.1111/1750-3841.14505

  197. 197.

    Li J., Zhang H., Wang G. Correlations between inflammatory response, oxidative stress, intestinal pathological damage and intestinal flora variation in rats with type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences. 2020;24(19):10162-10168.

    Not in our library10.26355/eurrev_202010_23236

  198. 198.

    Suman R. K., Ray Mohanty I., Borde M. K., Maheshwari U., Deshmukh Y. A. Development of an experimental model of diabetes co-existing with metabolic syndrome in rats. Advances in Pharmacological Sciences. 2016;2016.

    Not in our library10.1155/2016/9463476

  199. 199.

    Chan K. C., Kok K. E., Huang K. F., Weng Y. L., Chung Y. C. Effects of fermented red bean extract on nephropathy in streptozocin-induced diabetic rats. Food & Nutrition Research. 2020;64.

    Not in our library10.29219/fnr.v64.4272

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.